 |
Rockville, Maryland, USA and Suzhou, ChinaMay 22, 2026 /PRNewswire/ — Ascentage Pharma (Nasdaq: AAPG; HKEX: 6855), a leading biopharmaceutical company dedicated to developing innovative drugs in oncology and other fields, announced that the abstracts of six clinical studies selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting have been published on the ASCO website. Among these selected studies, three are rapid oral presentations and three are poster presentations, involving three key drug candidates: Olverembatinib (brand name: Nailike®), China’s first approved third-generation BCR-ABL inhibitor; Lisaftoclax (brand name: Lishengtuo®), China’s first domestically developed and approved selective Bcl-2 inhibitor; and Alrizomadlin (APG-115), an MDM2-p53 inhibitor.
The 2026 ASCO Annual Meeting will be held from May 29 to June 2 (local US time) at the McCormick Convention Center in Chicago, in a hybrid format combining online and in-person sessions. The annual ASCO meeting is the most important and authoritative academic exchange event in the global oncology field, showcasing the latest cutting-edge clinical oncology research achievements and cancer treatment technologies worldwide.
Key information from Ascentage Pharma’s abstracts selected for the 2026 ASCO Annual Meeting is as follows:
Rapid Oral Presentations
Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)
Abstract Number: 6513
Presentation Format: Rapid Oral Presentation
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Presentation Time:
May 30, 2026, 13:51–13:57 (Central Daylight Time)
May 31, 2026, 2:51–2:57 AM (Beijing Time)
First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA
Key Highlights:
- This multicenter, open-label Phase Ib study explored the combination of olverembatinib and blinatumomab in patients with relapsed/refractory (R/R) Ph+ BCP-ALL or CML-LBP.
- Among 5 patients with positive measurable residual disease (MRD) and non-complete response (CR) at enrollment, 4 achieved CR and 2 achieved MRD negativity, with an overall manageable safety profile.
- This study is the first to validate the feasibility of olverembatinib combined with immunotherapy in CML-LBP and R/R Ph+ BCP-ALL in an international patient population.
Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML)
Abstract Number: 6510
Presentation Format: Rapid Oral Presentation
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Presentation Time:
May 30, 2026, 13:21–13:27 (Central Daylight Time)
May 31, 2026, 2:21–2:27 AM (Beijing Time)
First Author: Professor Weiming Li, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Key Highlights:
- This is a single-arm, multicenter, open-label study conducted in China evaluating the efficacy and safety of olverembatinib as a second-line treatment.
- Among 42 evaluable patients, at cycle 24, the complete cytogenetic response (CCyR) rate was 91.3%, and the major molecular response (MMR) rate was 60.9%. In 32 patients who failed first-line treatment with second-generation TKIs, 81.3% still achieved CCyR and 50% achieved MMR, with a favorable safety profile.
- Olverembatinib demonstrated good tolerability and yielded high MMR and CCyR rates in CP-CML patients resistant/intolerant to first-line TKIs without T315I mutations.
Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Abstract Number: 10012
Presentation Format: Rapid Oral Presentation
Session Title: Pediatric Oncology II
Presentation Time:
May 30, 2026, 8:00–8:06 (Central Daylight Time)
May 30, 2026, 21:00–21:06 (Beijing Time)
First Author: Professor Yizhuo Zhang, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Key Highlights:
- This is a domestic multicenter clinical trial evaluating the safety and preliminary efficacy of alrizomadlin (APG-115) alone or in combination with lisaftoclax in heavily pretreated pediatric patients with relapsed/metastatic rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, and other soft-tissue sarcomas.
- Results showed no dose-limiting toxicities (DLTs) in either the monotherapy or combination group. Adverse events were primarily gastrointestinal and hematologic toxicities, with rare severe adverse events and no treatment-related deaths or discontinuations. In terms of efficacy, one patient with refractory rhabdomyosarcoma in the monotherapy group achieved CR; the combination group achieved an objective response rate (ORR) of 30% and a disease control rate (DCR) of 80%.
- The regimen demonstrated a manageable safety profile and preliminary antitumor activity in pediatric solid tumors, warranting further investigation.
Poster Presentations
Updated clinical and translational results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient tumors
Abstract Number: 11539
Presentation Format: Poster Presentation
Session Title: Sarcoma
Presentation Time:
June 1, 2026, 13:30–16:30 (Central Daylight Time)
June 2, 2026, 2:30–5:30 AM (Beijing Time)
First Author: Professor Haibo Qiu, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Key Highlights:
- This study in SDH-deficient tumors evaluated the efficacy of olverembatinib in patients with SDH-deficient GIST and paraganglioma.
- Among 26 patients with SDH-deficient GIST, 6 (23.1%) achieved a best response of PR, with a median progression-free survival (PFS) of 25.7 months; among 6 patients with SDH-deficient paraganglioma, 4 patients had a best response of SD lasting ≥4 cycles (CBR, 66.7%), with a median PFS of 8.25 months.
- This study is the first to elucidate a novel mechanism by which olverembatinib inhibits fatty acid-promoted tumor cell migration through the p38-CD36 pathway, providing a new approach for treating SDH-deficient tumors.
A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress
Abstract Number: TPS6608
Presentation Format: Poster Presentation
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Presentation Time:
June 1, 2026, 9:00–12:00 (Central Daylight Time)
June 1, 2026, 22:00–June 2, 1:00 AM (Beijing Time)
First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA
Key Highlights:
- POLARIS-2 is a global, multicenter, randomized, open-label Phase 3 registrational study.
- The study includes two independent cohorts. Part A randomizes CP-CML patients who have received at least two prior TKIs in a 2:1 ratio to olverembatinib or bosutinib; Part B is a single-arm study evaluating olverembatinib in patients with T315I mutations. The primary endpoint for both is the 24-week major molecular response rate.
A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress
Abstract Number: TPS7101
Presentation Format: Poster Presentation
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Presentation Time:
June 1, 2026, 9:00–12:00 (Central Daylight Time)
June 1, 2026, 22:00–June 2, 1:00 AM (Beijing Time)
First Author: Matthew Steven Davids, MD, Dana-Farber Cancer Institute, USA
Key Highlights:
- GLORA is a global, multicenter, open-label Phase 3 registrational study.
- This study aims to evaluate the efficacy and safety of lisaftoclax in combination with a BTK inhibitor in CLL/SLL patients who have received ≥12 months of BTK inhibitor monotherapy without achieving CR and without disease progression. The study plans to enroll approximately 440 patients across 126 centers in 18 countries and is currently recruiting.
About Ascentage Pharma
Ascentage Pharma (Nasdaq: AAPG; HKEX: 6855) is a comprehensive global biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs to address unmet clinical needs in oncology for patients worldwide. The company has established a rich pipeline of innovative drug candidates, including inhibitors targeting key proteins in the apoptosis pathway such as Bcl-2 and MDM2-p53, next-generation inhibitors targeting kinase mutations arising in cancer treatment, and protein degraders.
The company’s core product, Nailike®, is China’s first approved third-generation BCR-ABL inhibitor, approved for treating patients with chronic-phase chronic myeloid leukemia (CML-CP) and accelerated-phase CML (CML-AP) with T315I mutations, as well as adult patients with CML-CP resistant and/or intolerant to first- and second-generation TKIs. All approved indications for this drug have been included in China’s National Reimbursement Drug List (NRDL). Currently, Ascentage Pharma is conducting three global registrational Phase 3 clinical studies for Nailike®: the POLARIS-1 study, authorized by the US FDA and European EMA, evaluating Nailike® in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients; the POLARIS-2 study, authorized by the US FDA and European EMA, evaluating Nailike® in pretreated adult CML-CP patients; and the POLARIS-3 study evaluating Nailike® in patients with SDH-deficient GIST.
Another key product, Lishengtuo®, is a novel Bcl-2 inhibitor for treating various hematologic malignancies. Lishengtuo® has been approved by China’s National Medical Products Administration (NMPA) for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. Currently, Ascentage Pharma is conducting four global registrational Phase 3 clinical studies for Lishengtuo®: the GLORA study, authorized by the US FDA and European EMA, evaluating Lishengtuo® in combination with a BTK inhibitor in CLL/SLL patients who have received BTK inhibitor therapy for more than 12 months with suboptimal response; the GLORA-2 study evaluating Lishengtuo® as first-line treatment in treatment-naïve CLL/SLL patients; the GLORA-3 study evaluating Lishengtuo® as first-line treatment in newly diagnosed elderly or unfit AML patients; and the GLORA-4 study, authorized by the US FDA and European EMA, evaluating Lishengtuo® as first-line treatment in newly diagnosed intermediate- to high-risk MDS patients.
Leveraging its strong R&D capabilities, Ascentage Pharma has established a global intellectual property layout and has entered into global collaborations with numerous leading biopharmaceutical companies, including Takeda, AstraZeneca, Merck & Co., Pfizer, and Innovent, as well as research partnerships with academic institutions such as Dana-Farber Cancer Institute, Mayo Clinic, the National Cancer Institute, and the University of Michigan. For more information, please visit https://ascentage.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact in this press release may constitute forward-looking statements, including opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events, operating results, or financial condition of Ascentage Pharma.
These forward-looking statements are subject to numerous risks and uncertainties, as detailed in Ascentage Pharma’s filings with the U.S. Securities and Exchange Commission (SEC), including the “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” sections in the amended Registration Statement on Form F-1 filed on January 21, 2025, and the Annual Report on Form 20-F filed on April 16, 2025, the “Forward-Looking Statements” and “Risk Factors” sections in the prospectus for its initial public offering filed on October 16, 2019, and other documents filed with the SEC or HKEX from time to time. These factors could cause actual results, performance, achievements, or outcomes to differ materially from those expressed or implied in the forward-looking statements. The statements in this forward-looking statement do not constitute a profit forecast by the company’s management.
Accordingly, these forward-looking statements should not be regarded as predictions of future events. The forward-looking statements in this press release are based solely on Ascentage Pharma’s current expectations and judgments regarding future developments and their potential impact, and speak only as of the date they are made. Ascentage Pharma undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.